Antipyretic　acetaminophen　(APAP)　is　a　commonly　used　drug　that　generally　associates　with　liver　injury.　(-)-Epigallocatechin-3-gallate　(EGCG),　an　active　polyphenol　extracted　from　green　tea,　is　extensively　reported　to　have　the　potential　to　impact　a　variety　of　human　diseases.　However,　few　studies　were　reported　regarding　the　protective　effect　of　EGCG　on　APAP-induced　liver　injury　and　the　mechanism　is　still　unclear.　In　this　study,　in-vitro　and　in-vivo　experiments　were　carried　out　to　verify　the　hepatoprotective　effect　of　EGCG　against　APAP-induced　liver　injury　and　explore　the　potential　mechanism.　Results　indicated　that　EGCG　effectively　relieved　the　liver　injury　caused　by　APAP,　as　well　as　APAP-induced　mitochondrial　dysfunction.　The　protective　role　of　EGCG　was　not　only　attributed　to　its　antioxidant　capacity;　but　also　might　be　related　to　the　protective　effect　on　hepatic　mitochondrial　impairment;　based　on　that,　EGCG　could　improve　the　membrane　potential　and　activities　of　the　respiratory　chain　complexes　in　liver　mitochondria.　Our　study　casts　a　new　light　on　the　mechanism　of　EGCG＇s　hepatoprotective　effect　and　suggests　that　EGCG　has　considerable　potential　in　developing　tonics　for　relieving　APAP-induced　liver　injury.